Elkhorn Partners Limited Partnership acquired a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 1,000 shares of the company’s stock, valued at approximately $54,000.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Global Trust Asset Management LLC raised its holdings in shares of CRISPR Therapeutics by 150.0% during the 2nd quarter. Global Trust Asset Management LLC now owns 500 shares of the company’s stock worth $27,000 after acquiring an additional 300 shares during the period. Larson Financial Group LLC raised its holdings in shares of CRISPR Therapeutics by 95.5% during the 2nd quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock worth $31,000 after acquiring an additional 276 shares during the period. GPS Wealth Strategies Group LLC raised its holdings in shares of CRISPR Therapeutics by 99.7% during the 2nd quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company’s stock worth $33,000 after acquiring an additional 307 shares during the period. Riggs Asset Managment Co. Inc. raised its holdings in shares of CRISPR Therapeutics by 66.7% during the 1st quarter. Riggs Asset Managment Co. Inc. now owns 500 shares of the company’s stock worth $34,000 after acquiring an additional 200 shares during the period. Finally, Principal Securities Inc. purchased a new position in shares of CRISPR Therapeutics during the 4th quarter worth $41,000. Hedge funds and other institutional investors own 69.20% of the company’s stock.
Insider Buying and Selling
In related news, COO Julianne Bruno sold 3,366 shares of the business’s stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $56.09, for a total transaction of $188,798.94. Following the sale, the chief operating officer now owns 6,745 shares of the company’s stock, valued at $378,327.05. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 4.10% of the stock is owned by insiders.
Analyst Ratings Changes
Get Our Latest Stock Report on CRISPR Therapeutics
CRISPR Therapeutics Stock Performance
NASDAQ CRSP opened at $49.87 on Wednesday. The firm has a market cap of $4.23 billion, a PE ratio of -18.33 and a beta of 1.68. CRISPR Therapeutics AG has a one year low of $37.55 and a one year high of $91.10. The firm’s fifty day moving average is $50.91 and its two-hundred day moving average is $57.51.
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last issued its earnings results on Monday, August 5th. The company reported ($1.49) earnings per share for the quarter, missing the consensus estimate of ($1.43) by ($0.06). The firm had revenue of $0.52 million for the quarter, compared to analyst estimates of $12.31 million. The firm’s quarterly revenue was down 99.3% on a year-over-year basis. During the same quarter last year, the firm posted ($0.98) earnings per share. Research analysts predict that CRISPR Therapeutics AG will post -5.6 earnings per share for the current year.
About CRISPR Therapeutics
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
See Also
- Five stocks we like better than CRISPR Therapeutics
- Want to Profit on the Downtrend? Downtrends, Explained.
- Seize the Opportunity: Beyond Meat’s New Steak Could Spark Growth
- What is the Nikkei 225 index?
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report).
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.